Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: Possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine

Pharmacogenetics

Volumn 9, Issue 2, 1999, Pages 171-181

  Vorhees, Charles V ^a,e   Morford, LaRonda L ^a   Inman, Sandra L ^a   Reed, Tracy M ^a   Schilling, Mary A ^a,b   Cappon, Gregg D ^a,c   Moran, Mary S ^a   Nebert, Daniel W ^d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b College of Mount Saint Joseph ^*  (United States)

^c WIL RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Cytochrome P450; d methamphetamine; Dark Agouti rat inbred strain; Developmental neurotoxicity; Human CYP2D6 gene; Morris maze; Rat CYP2D2 gene; Sprague Dawley rat strain

Indexed keywords

CYTOCHROME P450 ISOENZYME; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME POLYMORPHISM; LEARNING; MAZE TEST; MEMORY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL DISCRIMINATION; STARTLE REFLEX; STRAIN DIFFERENCE; SWIMMING;

ANIMALS; ANIMALS, NEWBORN; ARYL HYDROCARBON HYDROXYLASES; BEHAVIOR, ANIMAL; BODY WEIGHT; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; LEARNING; MALE; METHAMPHETAMINE; POLYMORPHISM, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; STARTLE REACTION;

AGOUTI; ANIMALIA;

EID: 0032773876     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Al-Dabbagh SG, Idle JR, Smith RL. Animal modeling of human polymorphic drug oxidation - the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 1981; 33:161-164.
2. Baba T, Yamada H, Oguri K, Yoshimura H. Participation of cytochrome P-450 isozymes in N-demethylation, N-hydroxylation and aromatic hydroxylation of methamphetamine. Xenobiotica 1988; 18:475-484.
3. Bayer SA, Altman J, Russo RJ, Zhang X. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 1993; 14:83-144.
4. Boobis AR, Seddon CE, Davies DS, Bufuralol l'-hydroxylase activity of the rat: strain differences and the effects of inhbitors. Biochem Pharmacol 1986: 35:2961-2965.
5. Brandeis R, Brandys Y, Yehuda S. The use of the Morris water maze in the study of memory and learning. Int J Neurosci 1989; 48:29-69.
6. Cho AK. Ice: a new dosage form of an old drug. Science 1990; 249:631-634.
7. Churchill PF, Churchill SA, Martin MV, Guengerich FP. Characterization of a rat liver cytochrome P-450UT-H cDNA clone and comparison of mRNA levels with catalytic activity. Mol Pharmacol 1987; 31:152-158.
8. Colado MI, Williams JL, Green AR. The hyperthermic and neurotoxic effects of 'ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 1995; 115:1281-1289.
9. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993; 3:61-70.
10. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. 1996, Nomenclature for human CPY2D6 alleles. Pharmacogenetics 1996; 6:193-201.
11. Davis M, Eaton RC. Neural mechanisms of startle behavior. In: Davis M, Eaton RC, editors. The mammalian startle response. New York: Plenum Press: 1984. p. 287-351.
12. Derlet RW, Heischober B. Methamphetamine: stimulant of the 1990s? West J Med 1990; 153:625-628.
13. Dixon SD. Effects of transplacental exposure to cocaine and methamphetamine on the neonate. Western J Med 1989; 150:436-442.
14. Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: Incidence and clinical correlates. J Pediatr 1989; 115:770-778.
15. Dring LG, Smith RL, Williams RT. The metabolic fate of amphetamine in man and other species. Biochem J 1970; 116:425-435.
16. Eichelbaum M, Polymorphic drug oxidation in humans. Fed Proc 1984; 43:2298-2302.
17. Gallagher M, Burwell R, Burchinal M. Severity of spatial learning impairment in aging: Development of a learning index for performance in the Morris water maze. Behav Neurosci 1993; 107:618-626.
18. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokin Concepts 1994; 26:59-70.
19. Gonzalez FJ, Matsunaga T, Nagata K, Meyer U, Nebert DW, Pastewka J. et al. Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis in the DA rat polymorphism. DNA 1987; 6:149-161.
20. Holson RR, Pearce B. Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species. Neurotoxicol Teratol 1992; 14:221-228.
21. Idle JR, Smith RL. Polymorphisms of oxidation at carbon centers of drug and their clinical significance. Drug Metab Rev 1979; 9:301-317.
22. Kalow W, Bertilsson L. Interethnic factors affecting drug response. Adv Drug Res 1994; 23:1-53.
23. Larrey D, Disterath LM, Dannan GA, Wilkinson GR, Guengerich FP. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 1984; 23:2787-2795.
24. Little BB, Snell LM, Gilstrap LC. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol 1988; 72:541-544.
25. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Acta Psychiatr Scand 1993: 87:23-28.
26. Lucot JB, Wagner GC, Schuster CR, Seiden LS. Decreased sensitivity of rat pups to long-lasting dopamine and serotonin depletions produced by methylamphetamine. Brain Res 1982; 247:181-183.
27. Matsunaga E, Zanger UM, Hardwick JP, Gelboin HV, Meyer UA, Gonzalez FJ. The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 1989; 28:7349-7355.
28. Meyer U. Genetic polymorphisms of drug metabolism. Fundam Clin Pharmacol 1990; 4:595-615.
29. Morris RGM. Spatial localization does not require the presence of local cues. Learn Motiv 1981; 12:239-260.
30. Morris RGM. Developments of a water-maze procedure for studying spatial learning in the rat. J Nuerosci Methods 1984; 11:47-60.
31. Morris RGM, Davis S, Butcher SP. Hippocampal synaptic plasticity and NMDA receptors: a role in information storage? Phil Trans R Soc Lond 1990; 329:187-204.
32. Muralidharan G, Midha KK, McKay G, Hawes EM, Inaba T. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Xenobiotica 1989; 19:189-197.
33. Muralidharan G, Hawes EM, McKay G, Korchinski ED, Midha KK. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Eur J Clin Pharmacol 1991a; 41:471-474.
34. Muralidharan G, Hawes EM, McKay G, Midha KK. Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Xenobiotica 1991b; 21:1441-1450.
35. Nebert DW. Pharmacogenetics: 65 candles in the cake. Pharmacogenetics 1997a; 7:435-440.
36. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical significance and why to they exist? Am J Hum Genet 1997b; 60:265-271.
37. Nebert DW, Ingelman-Sundberg M, Daly AK. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme (DME) genes, their functional importance, and nomenclature issues. Drug Metab Rev 1999, in press.
38. Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates. J Pediatr 1987; 111:571-578.
39. Rosen JB, Hitchcock JM, Sananes CB, Miserendino MJD, Davis M. A direct projection from the central nucleus of the amygdala to the acoustic startle pathway: anterograde and retrograde tracing studies. Behav Neurosci 1991; 105:817-825.
40. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
41. Schulz-Utermoehl T, Bennett A, Ellis S, Tucker GBA, Edwards R. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 1999, (in press).
42. Seiden LS, Ricaurte GA. Neurotoxicity of methamphetamine and related drugs. In: Psychopharmacology: the third generation of progress. Meltzer Y (editor). New York: Raven press: 1987. P. 359-366.
43. Sellers EM, Otton SV, Tyndale RF. The potential role of the cytochrome P-450 2D6 pharmacokinetic polymorphism in drug abuse. NIDA Research Monograph Series 1997; 173:6-26.
44. Vorhees CV, Ahrens KG, Acuff-Smith KD, Schilling MA, Fisher JE. Methamphetamine exposure during early postnatal development in rats: I. Acoustic startle augmentation and spatial learning deficits. Psychopharmacology 1994a; 114:392-401.
45. Vorhees CV, Ahrens KG, Acuff-Smith KD, Schilling MA, Fisher JE. Methamphetamine exposure during early postnatal development in rats: II. Hypoactivity and altered responses to pharmacological challenge. Psychopharmacology 1994b; 114:402-408.
46. Vorhees CV, Reed TM, Schilling MS, Acuff-Smith KD, Fisher JE, Moran MS. Neonatal methamphetamine-induced long-term startle facilitation in rats as a function of prepulse stimulus intensity. Neurotoxicol Teratol 1996; 18:135-139.
47. Vorhees CV, Reed TM, Schilling MA, Fisher JE, Moran MS, Cappon GD, Nebert DW. CYP2D1 polymorphism in methamphetamine-treated rats: genetic differences in neonatal mortality and a comparison of spatial learning and acoustic startle. Neurotoxicol Teratol 1998; 20:265-273.
48. Wagner GC, Schuster CR, Seiden LS. Neurochemical consequences following administration of CNS stimulants to the neonatal rat. Pharmacol Biochem Behav 1981; 14:117-119.
49. Yamamoto Y, Tasaki T, Nakamura A, Iwata K, Kazusaka A, Gonzalez FJ, Fujita S. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 1998; 8:73-82.